Remarkable prolonged progression-free survival time after therapy with trifluridine/ tipiracil. A case report of 57-year-old woman with metastatic colorectal cancer

• Authors: Marlena Orlikowska
• Languages of publication: EN

Abstracts

EN

Colorectal cancer is the second leading cause of cancer-related death worldwide. Trifluridine/tipiracil is a novel orally administered antineoplasmatic thymidine-based nucleoside analog which represents an approved option for the treatment of advanced metastatic colorectal cancer in patients who are refractory, or are not considered candidates for, currently available therapies. In this report, we present a case of chemotherapy using trifluridine/tipiracil confirming the effectiveness of this drug primarily in the term of prolongation of progression free survival.

Keywords

EN

chemotherapy; colorectal cancer; trifluridine/tipiracil

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Education
• Journal: OncoReview
• Year: 2020
• Volume: 10
• Issue: 1
• Pages: 27-30

Contributors

author

Marlena Orlikowska

• Oncology and Chemotherapy Outpatient Clinic, Hospital in Starogard Gdański

References

• 1. International Agency for Research on Cancer: GLOBOCAN 2018. http://gco.iarc.fr/today/data/factsheets/cancers/10_8_9-Colorectum-fact-sheet. pdf.
• 2. Center MM, Jemal A, Smith RA et al. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009; 59: 366-78.
• 3. Wilkes GM. Metastatic colorectal cancer: management challenges and opportunities. Oncology. 2011; 25(7): 32-44.
• 4. Lenz HJ, Stintzing S, Loupakis F. TAS-102, a novel antitumor agent: a review of the mechanism of action. Cancer Treatment Rev. 2015; 41: 777-83.
• 5. Burness CB, Duggan ST. Trifluridine/tipiracil: a review in metastatic colorectal cancer. Drugs. 2016; 76: 1393-402.
• 6. Mayer R, Van Cutsem E, Falcone A et al. RECOURSE Study Group Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015; 372: 1909-19.
• 7. Van Cutsem E, Cervantes A, Adam R et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016; 27 (8): 1386-422.
• 8. European Medicines Agency. European public assessment report (EPAR) for Lonsurf. 2016. http://www.ema.europa.eu.

• Document Type: article